Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

2Total
P 2 (1)
P 3 (1)

Trial Status

Recruiting1
Withdrawn1
Active Not Recruiting1
Unknown1

Clinical Trials (4)

Showing 4 of 4 trials
NCT03701399Phase 3Active Not Recruiting

Troriluzole in Adult Participants With Spinocerebellar Ataxia

NCT01793168Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

NCT04495426UnknownPrimary

Genetic Mechanism of Conserved Ancestral Haplotype in SCA10

NCT04301284Phase 2Withdrawn

Study of CAD-1883 for Spinocerebellar Ataxia

Showing all 4 trials

Research Network

Activity Timeline